Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

US pharma major Eli Lilly (NYSE: LLY) yesterday announced executive leadership transitions that will further enhance the ...

Market volatility and near-term uncertainty can be challenging to deal with these days -- or at any time. Let's consider four ...

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...

Ozempic is what's known as a GLP-1, a drug class that's prescribed to manage Type 2 diabetes and is effective for weight loss ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

WeightWatchers, officially rebranded as WW International ( NASDAQ: WW ), has blamed its financial woes on the GLP-1 drug wave ...

2025 is going to be a year of great change. At a macro level, political and geopolitical shifts around the world will reshape relations. Regulation and deregulation may alter processes. And any ...